IBKS No2 SPAC (204840) - Total Assets
Based on the latest financial reports, IBKS No2 SPAC (204840) holds total assets worth ₩48.60 Billion KRW (≈ $32.94 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IBKS No2 SPAC (204840) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
IBKS No2 SPAC - Total Assets Trend (2015–2025)
This chart illustrates how IBKS No2 SPAC's total assets have evolved over time, based on quarterly financial data. See IBKS No2 SPAC book value and equity for net asset value and shareholders' equity analysis.
IBKS No2 SPAC - Asset Composition Analysis
Current Asset Composition (December 2025)
IBKS No2 SPAC's total assets of ₩48.60 Billion consist of 44.4% current assets and 55.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.2% |
| Accounts Receivable | ₩7.11 Billion | 14.6% |
| Inventory | ₩10.96 Billion | 22.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.31 Billion | 2.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how IBKS No2 SPAC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IBKS No2 SPAC market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IBKS No2 SPAC's current assets represent 44.4% of total assets in 2025, a decrease from 73.8% in 2015.
- Cash Position: Cash and equivalents constituted 6.2% of total assets in 2025, down from 8.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 22.4% of total assets.
IBKS No2 SPAC Competitors by Total Assets
Key competitors of IBKS No2 SPAC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $36.83 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Laurus Labs Limited
NSE:LAURUSLABS
|
India | Rs94.15 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Hypera S.A
SA:HYPE3
|
Brazil | R$29.50 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
IBKS No2 SPAC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.95 | 1.47 | 2.97 |
| Quick Ratio | 0.48 | 0.84 | 2.38 |
| Cash Ratio | 0.00 | 0.42 | 1.74 |
| Working Capital | ₩-1.07 Billion | ₩6.96 Billion | ₩9.34 Billion |
IBKS No2 SPAC - Advanced Valuation Insights
This section examines the relationship between IBKS No2 SPAC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.47 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 15.0% |
| Total Assets | ₩48.81 Billion |
| Market Capitalization | $43.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values IBKS No2 SPAC's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: IBKS No2 SPAC's assets grew by 15.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for IBKS No2 SPAC (2015–2025)
The table below shows the annual total assets of IBKS No2 SPAC from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩48.81 Billion ≈ $33.08 Million |
+15.02% |
| 2024-12-31 | ₩42.44 Billion ≈ $28.76 Million |
+6.45% |
| 2023-12-31 | ₩39.87 Billion ≈ $27.02 Million |
-2.41% |
| 2022-12-31 | ₩40.85 Billion ≈ $27.69 Million |
+28.09% |
| 2021-12-31 | ₩31.89 Billion ≈ $21.61 Million |
-8.73% |
| 2020-12-31 | ₩34.94 Billion ≈ $23.68 Million |
+31.63% |
| 2019-12-31 | ₩26.55 Billion ≈ $17.99 Million |
-15.89% |
| 2018-12-31 | ₩31.56 Billion ≈ $21.39 Million |
+110.11% |
| 2017-12-31 | ₩15.02 Billion ≈ $10.18 Million |
+21.62% |
| 2016-12-31 | ₩12.35 Billion ≈ $8.37 Million |
+39.33% |
| 2015-12-31 | ₩8.86 Billion ≈ $6.01 Million |
-- |
About IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disea… Read more